Arp-T1 Inhibitors
Arp-T1 inhibitors function through a variety of detailed cellular mechanisms that ultimately converge on the reduction of Arp-T1 activity within cells. One method involves the disruption of the PI3K/AKT signaling pathway, a critical route for mediating various cellular responses, including those that govern the functional state of Arp-T1. Chemical inhibitors targeting PI3K or mTOR within this pathway lead to a significant decline in the phosphorylation events necessary for Arp-T1 activation, thereby reducing its activity. Furthermore, specific kinase inhibitors that impede the MAPK signaling cascade also serve as indirect Arp-T1 inhibitors by preventing the phosphorylation of key substrates required for Arp-T1's activation. This is achieved by attenuating the activity of ERK or JNK, enzymes that are upstream in the signaling process and essential for Arp-T1's regulatory function.
Moreover, the inhibition of Src family kinases, which are upstream modulators in multiple cellular pathways, can cause a reduction in Arp-T1 activity through decreased substrate phosphorylation and activation. These specific kinase inhibitors, alongside proteasome inhibitors, alter cellular regulatory mechanisms, leading to a decrease in Arp-T1's activity. The latter does so by inducing the accumulation of proteins that negatively impact the ubiquitin-proteasome pathway, indirectly affecting Arp-T1 function. Additional methods of inhibition include the targeting of JAK/STAT signaling, where inhibition of JAK2 leads to diminished Arp-T1 activity, and the direct inhibition of AKT phosphorylation, which is fundamental for Arp-T1's role within the cell.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A potent inhibitor of PI3K, LY294002 leads to the suppression of the PI3K/AKT signaling pathway. As Arp-T1 is downstream of this pathway, its functional activity is decreased due to the reduced phosphorylation and activation of AKT, which is necessary for Arp-T1 activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 specifically inhibits MEK1, which in turn attenuates the ERK/MAPK signaling cascade. Since ERK is required for the phosphorylation of certain substrates that interact with Arp-T1, the inhibition of this pathway indirectly results in reduced functional activity of Arp-T1. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
This compound inhibits p38 MAP kinase, thereby disrupting the p38 MAPK signaling pathway that contributes to the activation of Arp-T1. The inhibition of this pathway leads to decreased Arp-T1 activity due to lesser substrate availability for its function. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is an irreversible inhibitor of PI3K. It disrupts the PI3K/AKT signaling pathway, leading to a downregulation of Arp-T1 activity by preventing necessary phosphorylation events. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin selectively inhibits mTORC1, which is part of the mTOR signaling pathway. Arp-T1 function is tied to mTOR activity; thus, the inhibition of mTORC1 results in a decrease in Arp-T1 functional activity. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is an Src family kinase inhibitor, affecting multiple signaling pathways, including those that activate Arp-T1. By inhibiting Src kinases, PP2 reduces the phosphorylation and subsequent activation of Arp-T1. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which is involved in the stress-activated MAPK pathway. Inhibition of JNK leads to a reduction in Arp-T1 activity as signaling through this kinase is necessary for full Arp-T1 function. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a broad-spectrum tyrosine kinase inhibitor with a particular affinity for BCR-ABL and Src family kinases. As these kinases are upstream of Arp-T1, their inhibition by Dasatinib results in decreased activation and function of Arp-T1. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a proteasome inhibitor that can lead to the accumulation of regulatory proteins which negatively affect the ubiquitin-proteasome pathway, indirectly leading to reduced activity of Arp-T1 through altered protein degradation processes. | ||||||
Tyrphostin B42 | 133550-30-8 | sc-3556 | 5 mg | $26.00 | 4 | |
AG490 is a JAK2 inhibitor, and by inhibiting JAK2, it disrupts the JAK/STAT signaling pathway. Arp-T1 activity is partially regulated by this pathway, so AG490 leads to a decrease in Arp-T1 activity. | ||||||